AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05064748
Drug: Benvitimod
RxNorm normalized name: Benvitimod
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
Trial: NCT05916521
Drug: 0.454% stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush two times daily
Trial: NCT05916521
Drug: 0.76% sodium monofluorophosphate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush two times daily
Trial: NCT05916521
Drug: 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush two times daily
Trial: NCT04676776
Drug: Levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants receive 1.5 mg levonorgestrel on day 1
Trial: NCT04676776
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants receive 200 mg mifepristone on day 3
Trial: NCT06273020
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
Trial: NCT05403710
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Trial: NCT05369078
Drug: THR-1442 20mg Single dose
RxNorm normalized name: Thr
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
Trial: NCT04762459
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib 110mg PO once daily
Trial: NCT04762459
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligrams per square meter (mg/m²) Pemetrexed
Trial: NCT04762459
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
Trial: NCT05983276
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
Trial: NCT05983276
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
Trial: NCT06304909
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine group will receive 0.5 mcg/kg
Trial: NCT05983276
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent.
Trial: NCT05983276
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
Trial: NCT05322902
Drug: remimazolam group
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
Trial: NCT05322902
Drug: propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
Trial: NCT05012865
Drug: avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: as provided in real world practice
Trial: NCT05012865
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: as provided in real world practice
Trial: NCT05600881
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take their regular medication or a placebo (vitamin C)
Trial: NCT04681651
Drug: Sham Normobaric Hyperoxia
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
Trial: NCT04254640
Drug: Cladribine Injection
RxNorm normalized name: cladribine Injection
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
Trial: NCT04254640
Drug: Aclarubicin
RxNorm normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
Trial: NCT04254640
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
Trial: NCT04254640
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
Trial: NCT05466175
Drug: Olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05466175
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given Intravenous
Trial: NCT05466175
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given Intravenous
Trial: NCT05114759
Drug: SHR-A2009
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy.
Trial: NCT05574894
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone is supplemented during the ovarian stimulation till the day of trigger
Trial: NCT05574894
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol for ovarian stimulation
Trial: NCT05162131
Drug: Bentracimab (PB2452) 100 mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Bentracimab (DB16659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion
Trial: NCT05162131
Drug: Bentracimab (PB2452) 300 mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Bentracimab (DB16659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion
Trial: NCT05162131
Drug: Bentracimab (PB2452) 1000 mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Bentracimab (DB16659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion
Trial: NCT05162131
Drug: Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)
RxNorm normalized name: Ticagrelor
DrugBank: Bentracimab (DB16659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Trial: NCT05162131
Drug: Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)
RxNorm normalized name: Ticagrelor
DrugBank: Bentracimab (DB16659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Trial: NCT05162131
Drug: Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)
RxNorm normalized name: Ticagrelor
DrugBank: Bentracimab (DB16659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Trial: NCT02575508
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02575508
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02575508
Drug: pan FGFR Kinase Inhibitor BGJ398
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05162131
Drug: Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)
RxNorm normalized name: Ticagrelor
DrugBank: Bentracimab (DB16659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Trial: NCT05774756
Drug: Setmelanotide
RxNorm normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for daily subcutaneous injection
Trial: NCT06465732
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the active comparator arm receive dupilumab only
Trial: NCT06465732
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the experimental arm receive dupilumab plus tofacitinib.
Trial: NCT03432065
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
Trial: NCT06468423
Drug: Deferasirox (DFX)
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
Trial: NCT06468423
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
Trial: NCT00002351
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04677855
Drug: Dutasteride 0.5 mg
RxNorm normalized name: dutasteride 0.5 MG
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg capsules
Trial: NCT04677855
Drug: Abiraterone and Prednisone
RxNorm normalized name: niraparib and abiraterone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablets Abiraterone with 5 mg Prednisone Tablets
Trial: NCT00040430
Drug: 111In-DAC
RxNorm normalized name: DAC
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05659147
Drug: Secretin
RxNorm normalized name: Secretin
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study.
Trial: NCT00859001
Drug: FM+R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine-Mitoxantrone-Rituximab
Trial: NCT00859001
Drug: Zevalin (Ibritumomab Tiuxetan)
RxNorm normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05641051
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cases will receive 10 mg intravenous metoclopramide every 6 hours.
Trial: NCT05545111
Drug: NBI-1117568
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with orally administered NBI-1117568
Trial: NCT04390802
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
Trial: NCT04647669
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
Trial: NCT04647669
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg capsules twice daily every 12 h for 10 days taken with or without food.
Trial: NCT04647669
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
Trial: NCT05277701
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
Trial: NCT05724446
Drug: Clobetasol Propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
Trial: NCT05393063
Drug: AK127
RxNorm normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
Trial: NCT06031129
Drug: Butorphanol
RxNorm normalized name: Butorphanol
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
Trial: NCT04303702
Drug: Continue Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
Trial: NCT06085937
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 0.2mg/kg of IV ketamine
Trial: NCT06441344
Drug: Toripalimab plus Anlotinib
RxNorm normalized name: Toripalimab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
Trial: NCT06441344
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
Trial: NCT05919381
Drug: Gentuximab Injection
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Trial: NCT04791566
Drug: Dexamethasone 1 mg/kg
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
Trial: NCT01897740
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets of sildenafil 20 mg 3 times a day for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
Trial: NCT00001054
Drug: Valacyclovir hydrochloride
RxNorm normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no